Table 2.
Co‐occurrences and mutual exclusivities of mutated genes in colorectal adenocarcinoma data sets.
| Significant co‐occurrence | Significant mutual exclusivity | |||||
|---|---|---|---|---|---|---|
| Mutated genes | TCGA Nature 2012 Study | TCGA Pan Cancer Atlas Study | MSKCC 2018 Cancer Cell Study | TCGA Nature 2012 Study | TCGA Pan Cancer Atlas Study | MSKCC 2018 Cancer Cell Study |
| APC and CTNNB1 | 0 | 0 | 0 | 0 | 1 (0.014) | 1 (<0.001) |
| APC and KRAS | 0 | 1 (<0.001) | 1 (0.014) | 0 | 0 | 0 |
| APC and PIK3CA | 0 | 0 | 1 (0.019) | 0 | 0 | 0 |
| APC and TP53 | 0 | 1 (<0.001) | 1 (0.022) | 0 | 0 | 0 |
| CTNNB1 and FBXW7 | 0 | 1 (<0.001) | 0 | 0 | 0 | 0 |
| CTNNB1 and PIK3CA | 0 | 1 (<0.001) | 0 | 0 | 0 | 0 |
| CTNNB1 and RB1 | 0 | 1 (<0.001) | 0 | 0 | 0 | 0 |
| FBXW7 and KRAS | 0 | 0 | 1 (0.001) | 0 | 0 | 0 |
| FBXW7 and PIK3CA | 0 | 1 (0.012) | 1 (<0.001) | 0 | 0 | 0 |
| FBXW7 and TP53 | 0 | 0 | 0 | 0 | 0 | 1 (0.013) |
| FBXW7 and RB1 | 0 | 1 (0.014) | 1 (0.001) | 0 | 0 | 0 |
| KRAS and PIK3CA | 1 (<0.001) | 1 (<0.001) | 1 (<0.001) | 0 | 0 | 0 |
| KRAS and TP53 | 0 | 0 | 0 | 0 | 0 | 1 (<0.001) |
| PIK3CA and TP53 | 0 | 0 | 0 | 0 | 1 (<0.001) | 1 (<0.001) |
Values indicate the existence (1) or non‐existence (0) of significant co‐occurrence, or significant mutual exclusivity between the listed mutated genes in three different data sets according to The Cancer Genome Atlas Program 2012 (TCGA, [16]), TCGA Pan Cancer Atlas Study [17] and Memorial Sloan Kettering Cancer Center Study (MSKCC, [18]). No significant finding is shown in red, significant correlation in one data set is marked in orange and significant findings in two or more data sets are highlighted in green. P values are indicated in parenthesis.